Electrical cardiomyopathies contain the long QT syndrome (LQTS), the short QT 
syndrome (SQTS), the Brugada syndrome, and the catecholaminergic polymorphic 
ventricular tachycardia (CPVT). Patients diagnosed with an electrical 
cardiomyopathy have an increased risk of syncope and sudden cardiac death (SCD). 
Usually, we are dealing with young patients or even children. The prevalence of 
these diseases is low. No large prospective randomized studies exist with 
respect to outcome based on different clinical and genetic parameters. Thus, 
risk stratification in these patients is based on retrospective data from 
single- or multicenter registries.The implantable cardioverter defibrillator is 
the only reliable therapy in patients with Brugada syndrome and SQTS, as no 
pharmacological therapy has been proven to prevent SCD. In LQTS and CPVT, the 
primary therapy relies on beta-blockers. In high-risk patients, the ICD is 
indicated.In all electrical diseases, risk stratification is based on the 
clinical phenotype, including the electrocardiogram, the history of unexplained 
or disease-related syncope, and sudden cardiac arrest. In LQTS and CPVT, 
demographic data like age and gender are important factors for risk 
stratification. The genotype contributes to risk stratification only in LQTS and 
CPVT.Patients with electrical cardiomyopathies have to be risk-stratified 
individually based on the data and the current guidelines available.